SCHEMBL3665638

SCHEMBL3665638

NC(=O)c1cncc(Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.67
MKNK1 Q9BUB5 4/20 0.62
MKNK2 Q9HBH9 4/20 0.62
MAP4K4 O95819 1/20 0.53
PARP1 P09874 1/20 0.50
SMYD3 Q9H7B4 1/20 0.49
SIRT2 Q8IXJ6 3/20 0.45
SIRT1 Q96EB6 3/20 0.45
SIRT3 Q9NTG7 3/20 0.45
F7 P08709 1/20 0.45
F3 P13726 1/20 0.45
SARM1 Q6SZW1 1/20 0.45
SIRT6 Q8N6T7 1/20 0.45
SIRT5 Q9NXA8 1/20 0.45
SIRT4 Q9Y6E7 1/20 0.45
ALPL P05186 1/20 0.42
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2841794 0.84 SIRT2 (0.54) HCAR2MKNK1MKNK2MAP4K4SIRT2
SCHEMBL9446837 0.83 HCAR2 (0.62) HCAR2MKNK1MKNK2MAP4K4PARP1
Hydrazine SCHEMBL27966471 0.81 HCAR2 (0.92) HCAR2MKNK1MKNK2SMYD3
SCHEMBL30475721 0.80 HCAR2 (0.58) HCAR2MKNK1MKNK2MAP4K4PARP1
SCHEMBL4196968 0.80 HCAR2 (0.69) HCAR2MKNK1MKNK2SMYD3PKM
SCHEMBL486309 0.80 HCAR2 (1.00) HCAR2MKNK1MKNK2SMYD3
SCHEMBL29944817 0.80 HCAR2 (1.00) HCAR2MKNK1MKNK2SMYD3
SCHEMBL12127773 0.78 HCAR2 (0.55) HCAR2MKNK1MKNK2MAP4K4SMYD3
Hydrochloric Acid SCHEMBL10401123 0.78 HCAR2 (0.96) HCAR2MKNK1MKNK2SMYD3
SCHEMBL30936046 0.78 HCAR2 (0.55) HCAR2MKNK1MKNK2MAP4K4SMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111601790-B Heteroaryl compounds as protein kinase inhibitors 福建海西新药创制股份有限公司 2023-03-31 CN claimed
US-8841304-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-09-23 US claimed
US-20140221370-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-08-07 US claimed
EP-2242755-B1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2012-09-12 EP claimed
US-20100324041-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-12-23 US claimed
EP-2242755-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-10-27 EP claimed
WO-2009089352-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 WO claimed
CN-120019049-A Azole modulators of cholesterol biosynthesis and their use for promoting remyelination 基因泰克公司 2025-05-16 CN disclosed
CN-116715625-A Heteroaryl compounds as protein kinase inhibitors 福建海西新药创制股份有限公司 2023-09-08 CN disclosed
CN-111601790-B Heteroaryl compounds as protein kinase inhibitors 福建海西新药创制股份有限公司 2023-03-31 CN disclosed
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
CN-105939998-A Heteroaryl compounds as btk inhibitors and uses thereof 默克专利有限公司 2016-09-14 CN disclosed
CN-102159547-A Heterocyclic carboxamide compounds ASTELLAS PHARMA INC 2011-08-17 CN disclosed
CN-101959887-A Pyrrolopyridine as kinase inhibitor ARRAY BIOPHARMA INC 2011-01-26 CN disclosed
US-20100324041-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-12-23 US disclosed
EP-2242755-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-10-27 EP disclosed
WO-2009089352-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 WO disclosed
EP-0331052-A2 Process for the preparation of imidized acrylic polymers ELF ATOCHEM ITALIA S.r.l. (IT) 1989-09-06 EP disclosed
US-4192946-A Process for producing 3-hydroxy-5-halopyridines CIBA-GEIGY CORPORATION (US) 1980-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221370-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B HCAR2 4361/4885MKNK1 208/4885MKNK2 188/4885
US-20100324041-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B HCAR2 4326/4885MKNK1 202/4885MKNK2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.